Integra lifesciences
Integra LifeSciences Holdings Corporation, commonly referred to as Integra, is a prominent player in the medical technology industry, headquartered in the United States. Founded in 1989, the company has established itself as a leader in regenerative medicine and neurosurgery, with a strong presence in North America, Europe, and Asia. Integra's core offerings include advanced wound care products, neurosurgical solutions, and surgical instruments, distinguished by their innovative designs and commitment to improving patient outcomes. The company is particularly noted for its Integra Dermal Regeneration Template, which has revolutionised the treatment of complex wounds. With a robust market position, Integra has achieved significant milestones, including strategic acquisitions that have expanded its product portfolio and global reach. As a trusted partner in healthcare, Integra LifeSciences continues to drive advancements in surgical and regenerative solutions, enhancing the quality of care for patients worldwide.
DitchCarbon Score
How does Integra lifesciences's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Integra lifesciences's score of 36 is higher than 96% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Integra lifesciences's reported carbon emissions
In 2023, Integra LifeSciences reported total carbon emissions of approximately 156,706,000 kg CO2e from Scope 3, 8,277,000 kg CO2e from Scope 1, and 15,333,000 kg CO2e from Scope 2. This represents a notable decrease in Scope 1 emissions from 13,215,000 kg CO2e in 2022 and a reduction in Scope 2 emissions from 16,210,000 kg CO2e in the same year. In 2022, the company disclosed a total of 158,981,000 kg CO2e in Scope 3 emissions, alongside 13,215,000 kg CO2e in Scope 1 and 16,210,000 kg CO2e in Scope 2. The trend indicates a commitment to reducing their carbon footprint, particularly in direct emissions (Scope 1) and indirect emissions from energy consumption (Scope 2). Despite these reductions, Integra LifeSciences has not set specific reduction targets or climate pledges, which may limit their long-term sustainability goals. The company continues to monitor and report its emissions, demonstrating transparency in its environmental impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 13,902,000 | 00,000,000 | 0,000,000 |
| Scope 2 | 18,609,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Integra lifesciences is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
